These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23631205)

  • 1. [Type 2 diabetes and impaired glucose tolerance].
    Furukawa N; Araki E
    Nihon Rinsho; 2013 Feb; 71(2):270-4. PubMed ID: 23631205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
    Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
    Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proatherogenic lipid metabolism disturbances in impaired glucose tolerance].
    Okopień B; Stachura-Kułach A; Kułach A; Krysiak R; Herman ZS
    Pol Merkur Lekarski; 2005 Feb; 18(104):219-22. PubMed ID: 17877135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-Domínguez A; Comuzzie AG
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic implications of diabetes in cardiovascular disease.
    Cherian B; Meka N; Katragadda S; Arora R
    Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of diabetes in patients with severe obesity.
    Scheen AJ
    Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM).
    Corpeleijn E; Feskens EJ; Jansen EH; Mensink M; Saris WH; Blaak EE
    Diabetes Care; 2007 Dec; 30(12):3125-7. PubMed ID: 17890316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
    Wiedeman PE; Trevillyan JM
    Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platycodon grandiflorum modifies adipokines and the glucose uptake in high-fat diet in mice and L6 muscle cells.
    Ahn YM; Kim SK; Kang JS; Lee BC
    J Pharm Pharmacol; 2012 May; 64(5):697-704. PubMed ID: 22471365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latest research and development trends in non-insulin anti-diabetics.
    Cheon HG
    Arch Pharm Res; 2013 Feb; 36(2):145-53. PubMed ID: 23397318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
    Retnakaran R; Ye C; Hanley AJ; Harris SB; Zinman B
    Diabetes Obes Metab; 2012 Jan; 14(1):91-3. PubMed ID: 21812893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.
    Raz I; Eldor R; Cernea S; Shafrir E
    Diabetes Metab Res Rev; 2005; 21(1):3-14. PubMed ID: 15386813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Worsening factors for the progression of impaired glucose tolerance to diabetes mellitus learning from prospective studies].
    Kosaka K
    Nihon Rinsho; 1996 Oct; 54(10):2725-32. PubMed ID: 8914435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.